Fisetin for Longevity: Senolytic Activity and Brai…

Fisetin is a flavonoid found in small amounts in strawberries, apples, grapes, and onions. At the concentrations achievable through supplementation, it shows some of the most impressive longevity data of any naturally occurring compound — including a nearly 36% extension of median lifespan in old mice and meaningful clearance of senescent cells in human adipose tissue.

Senescent Cells: Why They Matter

Cellular senescence is the process by which damaged cells enter a permanent growth arrest rather than dying. These cells, nicknamed "zombie cells," accumulate with age and secrete a mixture of inflammatory cytokines, matrix metalloproteinases, and growth factors called the senescence-associated secretory phenotype (SASP). The SASP damages surrounding cells, disrupts tissue architecture, and drives chronic inflammation.

By age 70, senescent cells may constitute 7-8% of total cells in some tissues. They are implicated in fibrosis, osteoarthritis, atherosclerosis, neurodegeneration, and immune dysfunction. Removing them — the goal of senolytic therapy — is one of the most promising longevity strategies.

Fisetin vs. Quercetin: Comparing the Two Natural Senolytics

The natural senolytic landscape is led by two flavonoids: fisetin and quercetin. Both inhibit anti-apoptotic proteins in the Bcl-2 family (particularly Bcl-2, BCL-xL, and BCL-W), which senescent cells rely on for survival. When these survival signals are blocked, senescent cells preferentially undergo apoptosis, while normal cells (which have multiple survival pathways) are relatively unaffected.

In direct comparisons, fisetin shows greater senolytic potency than quercetin in cell culture. A 2018 study at Mayo Clinic (Kirkland lab) found fisetin was the most potent senolytic among ten flavonoids tested, with superior reduction of senescent cell burden in mouse tissues. The quercetin + dasatinib combination (D+Q) remains the clinical benchmark in human trials, but quercetin is rarely used alone at therapeutic doses.

The Mouse Lifespan Data

The 2018 paper in EBioMedicine reported that fisetin, administered to old mice beginning at 85 weeks of age, extended median lifespan by approximately 36% and maximum lifespan by about 27%. This is extraordinary for an intervention begun in aged animals. Treated mice also showed improvements in health markers, physical function, and reduced tissue inflammation compared to controls.

Human Evidence: The AFFIRM-LITE Trial

A Mayo Clinic pilot trial (AFFIRM-LITE) tested fisetin 20 mg/kg for two consecutive days in ten older adults with mild cognitive impairment. This translates to roughly 1,200-1,700 mg for a 60-80 kg person over two days. The study measured inflammatory biomarkers in the blood and found significant reductions in SASP factors including p21, PAI-1, and several cytokines compared to baseline. This was not a placebo-controlled trial, but it established human pharmacodynamic evidence for fisetin's senolytic activity at these doses.

Bcl-2 and BCL-xL Inhibition Mechanism

Senescent cells overexpress anti-apoptotic Bcl-2 family proteins as a survival mechanism. Fisetin acts as a natural BH3 mimetic — it occupies the hydrophobic groove where pro-apoptotic proteins would normally bind, preventing Bcl-2 and BCL-xL from blocking apoptosis. This mechanism is shared with the prescription drug navitoclax (ABT-263), though fisetin is less potent and more selective, which likely explains its favorable safety profile.

Pulse Dosing vs. Continuous Dosing

Because senolytics work by killing a population of cells rather than inhibiting an ongoing process, continuous daily dosing is not necessary and may not be optimal. The emerging clinical approach uses pulse dosing — taking a high dose for 2-3 consecutive days, then repeating monthly or quarterly.

For a typical adult (70 kg), the protocol based on human trial dosing would be approximately 1,000-1,500 mg/day for 2 days, taken monthly. Some practitioners use a once-weekly high-dose approach. Daily low-dose fisetin (100-200 mg) may provide neuroprotective and anti-inflammatory benefits through non-senolytic mechanisms, but this is distinct from senolytic therapy.

Neuroprotective Properties

Separate from senolysis, fisetin has impressive neuroprotective evidence. It activates ERK1/2 signaling (important for long-term memory), inhibits neuroinflammatory pathways, and crosses the blood-brain barrier. In Alzheimer's mouse models, fisetin supplementation reduced amyloid burden and improved cognitive performance. These mechanisms are relevant at lower doses than senolytic protocols.

Food Sources and Bioavailability

Strawberries are the richest natural source, providing approximately 160 mcg of fisetin per gram. To reach even 100 mg of fisetin from strawberries would require consuming roughly 600 grams. Supplementation is essential for senolytic or significant neuroprotective targets. Fisetin is fat-soluble, so taking it with a meal containing healthy fats improves absorption.

FAQ

Q: Is fisetin safe at senolytic doses (1,000+ mg)?

Human trial data at 20 mg/kg showed no significant adverse events. However, fisetin can inhibit certain drug-metabolizing enzymes (CYP3A4, CYP2C9). Consult a physician before using high-dose fisetin if you take prescription medications.

Q: How often should I take fisetin for senolytic effects?

The most common protocol is 2 consecutive days at 1,000-1,500 mg/day, repeated monthly. Quarterly pulse dosing may also be sufficient as new senescent cells accumulate relatively slowly.

Q: Can fisetin be taken daily at lower doses?

Yes, 100-200 mg/day is used by many for ongoing neuroprotection and anti-inflammatory effects without the senolytic dosing schedule.

Track your supplements in Optimize.

Fisetin for Longevity: Senolytic Activity and Brain Protection